Full Brilinta study results show the blood thinner reduces rate of secondary stroke

Full Brilinta study results show the blood thinner reduces rate of secondary stroke

Source: 
Endpoints
snippet: 

AstraZeneca once projected its Brilinta drug to peak at $3.5 billion in sales, and though the blood thinner never reached that lofty goal, it received the latest positive signs in a string of recent good news.